Librela – Injectable Pain Relief for Degenerative Joint Disease in Dogs

Librela is a monoclonal antibody treatment administered once a month, designed to control pain associated with degenerative joint disease (OA) in dogs.

Librela works by targeting Nerve Growth Factor (NGF), a key contributor to degenerative joint disease pain, helping to improve comfort, mobility, and quality of life.

Main Benefits:

• Provides long-term control of degenerative joint disease pain.

• Administered once a month by a veterinarian.

• Targets NGF involved in pain signaling.

• Helps improve daily mobility and comfort.

Indication: Pain control associated with degenerative joint disease in dogs.

Administration: Monthly injection under veterinary supervision.